Table 2.
Targets | Physiological effect in T cell | Gene editing | Tumor | Efficacy | Clinic trial | Reference |
---|---|---|---|---|---|---|
SOCS1 | Inhibiting cytokine reactivity | KO | Melanoma in mice | Suppressing tumor growth | Advanced solid tumors (NCT06237881) | [228] |
Regnase-1/Roquin-1 | Inhibiting inflammatory phenotype | KO | Melanoma in mice | Improving survival rate | N/A | [231] |
PTPN2 | Inducing differentiation of exhausted phenotype | KO | Melanoma in mice | Suppressing tumor growth | N/A | [150] |
RASA2 | Inhibiting TCR antigen sensitivity | KO | Melanoma in mice | Improving survival rate | N/A | [234] |
P38 | Inhibiting the differentiation of effector phenotype | KO | Melanoma in mice | Improving survival rate | N/A | [236] |
ARID1A | Inducing the occurrence of terminal exhaustion phenotype | KO | Melanoma in mice | Suppressing tumor growth | N/A | [237] |
CBLB | Inhibiting proximal TCR signaling | KO | Colon carcinoma in mice | Suppressing tumor growth | N/A | [345] |
CD5 | Inhibiting proximal TCR signaling | KO | Pancreatic carcinoma in mice | Suppressing tumor growth | N/A | [346] |
PRODH2 | Inducing immune metabolic remodeling | KI or OE | Breast carcinoma in mice | Suppressing tumor growth | N/A | [238] |
CARD11-PIK3R3 | Inducing effector and memory phenotype differentiation | KI or OE | Melanoma in mice | Improving survival rate | N/A | [239] |
KO: Knock-out, KI: Knock-in, OE: Overexpression, N/A: Not Applicable